Health ❯ Healthcare

Obesity Treatment

Weight Loss Drugs Weight Management Medications Weight Loss Medications GLP-1 Drugs GLP-1 Receptor Agonists GLP-1 Medications GLP-1 Agonists Eli Lilly Diabetes Management Oral Medications Bariatric Surgery Medication Management Market Competition Prescription Drugs Pharmaceuticals Biotechnology Self-Pay Programs Clinical Research Patient Access Drug Efficacy Incretin Medications GLP-1 Analogues Semaglutide Anti-Obesity Drugs Diabetes Medications Market Demand CagriSema Drug Affordability Pharmaceutical Products Medication Pricing Weight Loss Fat Injections Drug Sales Injectable Medications Long-term Care Pharmaceutical Research Diabetes Treatment

Mounjaro Study Finds Lower Heart‑Attack Risk as UK Safety Reports Rise

Officials say Yellow Card reports do not prove drugs caused harm.

Study Links GLP-1 Weight-Loss Drugs to Hair Shedding With Rapid Weight Loss

Novo Nordisk’s Oral Semaglutide Lowers HbA1c in Teens in Pivotal Trial

FDA Orders Post-Approval Safety Studies for Lilly’s Foundayo Weight-Loss Pill

GLP-1 Pills Accelerate into U.S. Care with Amazon Rollout and New Evidence on Use and Response

FDA Clears Eli Lilly’s Foundayo Oral GLP-1 for Weight Loss, With U.S. Launch Set for April 6

Studies Link GLP-1 Drugs to Lower Addiction and Overdose Risks

New Study Finds Nearly Fivefold Higher Reported ‘Eye Stroke’ Risk With Wegovy vs Ozempic

Lilly Launches FDA-Cleared Monthly Zepbound KwikPen on LillyDirect at $299 Starter Price

States Curb Medicaid Coverage as First GLP‑1 Weight‑Loss Pill Debuts and Cash Prices Fall

Lilly’s Daily Obesity Pill Sustains Weight Loss After Switch From Wegovy or Zepbound

Lilly Cuts Zepbound Cash Prices on LillyDirect as GLP‑1 Price Competition Deepens

Berenberg Upgrades Novo Nordisk to Buy, Sets DKK425 Price Target

FDA Ends GLP-1 Drug Shortages, Triggering New Pricing and Coverage Moves